Live Breaking News & Updates on கடுமையான மருந்துகள் இன்க்|Page 7
Stay updated with breaking news from கடுமையான மருந்துகள் இன்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Rigel Completes Patient Enrollment In Phase 2 Trial To Evaluate Fostamatinib In COVID-19 Patients WASHINGTON (dpa-AFX) - Rigel Pharmaceuticals, Inc. (RIGL) announced the completion of patient enrollment in a multi-center phase 2 clinical trial to evaluate the safety of fostamatinib, the company s oral spleen tyrosine kinase inhibitor, for the treatment of hospitalized COVID-19 patients. Treatment will be administered orally twice daily for 14 days. There will be a follow-up period to day 60. Fostamatinib is marketed in the U.S. as TAVALISSE tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia. Rigel expects to report topline data from the clinical trial in April 2021. ....
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Aerie Pharmaceuticals (NASDAQ:AERI) - The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
EARNINGS SUMMARY: Details of Rigel Pharmaceuticals Inc. Q4 Earnings Report finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - Fourth quarter total revenues of $18.5 million; full year total revenues of $108.6 million - Rigel will receive an upfront cash payment of $125 million from Lilly for the strategic collaboration to develop Rigel s RIP1 inhibitor program - Launched a Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients - Top line data from NIH/NHLBI-sponsored Phase 2 trial of fostamatinib in COVID-19 patients expected in April 2021 - Conference call and webcast today at 4:30PM Eastern Time News provided by Share this article Share this article SOUTH SAN FRANCISCO, Calif., March 2, 2021 /PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2020, including sales of TAVALISSE ....